Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Shinichiro Matsuda"'
Autor:
Jiahao Yang, Lu Liu, Yasuaki Oda, Keisuke Wada, Mako Ago, Shinichiro Matsuda, Miho Hattori, Tsukimi Goto, Yuki Kawashima, Yumi Matsuzaki, Takeshi Taketani
Publikováno v:
Stem Cell Research & Therapy, Vol 14, Iss 1, Pp 1-22 (2023)
Abstract Background Mitochondrial dysfunction caused by mutations in mitochondrial DNA (mtDNA) or nuclear DNA, which codes for mitochondrial components, are known to be associated with various genetic and congenital disorders. These mitochondrial dis
Externí odkaz:
https://doaj.org/article/04f5c029444e4985a8703536031f60cd
Autor:
Yu Yagi, Yusuke Kanemasa, Yuki Sasaki, Sotaro Goto, Yasuhiko Yamamura, Yusuke Masuda, Kumiko Fujita, Kento Ishimine, Yudai Hayashi, Mano Mino, An Ohigashi, Yuka Morita, Taichi Tamura, Shohei Nakamura, Toshihiro Okuya, Shinichiro Matsuda, Takuya Shimizuguchi, Naoki Shingai, Takashi Toya, Hiroaki Shimizu
Publikováno v:
Journal of Clinical & Experimental Hematopathology; 2024, Vol. 64 Issue 2, p107-118, 12p
Autor:
Taketani, Jiahao Yang, Lu Liu, Yasuaki Oda, Keisuke Wada, Mako Ago, Shinichiro Matsuda, Miho Hattori, Tsukimi Goto, Shuichi Ishibashi, Yuki Kawashima-Sonoyama, Yumi Matsuzaki, Takeshi
Publikováno v:
International Journal of Molecular Sciences; Volume 24; Issue 12; Pages: 10294
Mitochondria are essential organelles for maintaining intracellular homeostasis. Their dysfunction can directly or indirectly affect cell functioning and is linked to multiple diseases. Donation of exogenous mitochondria is potentially a viable thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::ee994e21056117d5803406145658d351
Autor:
Fumimasa Takahashi, Takaaki Miyake, Tsutomu Takahashi, Riruke Maruyama, Shunsuke Ito, Masaya Inoue, Ayumi Fujimoto, Koichi Ohshima, Takahiro Okada, Ritsuro Suzuki, Fumiyoshi Ikejiri, Yusuke Okada, Junji Suzumiya, Shinichiro Matsuda, Fumiko Arakawa
Publikováno v:
American Journal of Clinical Pathology. 155:308-317
Objectives We report a rare case of B-lymphoblastic lymphoma (B-LBL) and low-grade follicular lymphoma (FL) identified concurrently in biopsies from different sites at the initial diagnosis in a 39-year-old man. The clonal relationship between the 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77154ac6ed38a163b84cdf545f465d77
https://doi.org/10.1093/ajcp/aqaa126
https://doi.org/10.1093/ajcp/aqaa126
Autor:
Ichiro Moriyama, Fumimasa Takahashi, Shinichiro Matsuda, Fumiyoshi Ikejiri, Masaya Inoue, Kenji Tamura
Publikováno v:
Annals of Oncology. 33:S543
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4cf8152f3aed57db61040e6ed735acb3
https://doi.org/10.1016/j.annonc.2022.05.354
https://doi.org/10.1016/j.annonc.2022.05.354
Autor:
Tsutomu Takahashi, Tomonori Nakazato, Isao Yoshida, Ritsuro Suzuki, Naoto Tomita, Youko Suehiro, Kazuyuki Shimada, Noriko Fukuhara, Yoshitaka Imaizumi, Motoko Yamaguchi, Junji Suzumiya, Koji Izutsu, Shinichiro Matsuda, Kana Miyazaki
Publikováno v:
International journal of hematology. 112(6)
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) −/+ rituximab (R) is the standard chemotherapeutic regimen for aggressive lymphoma, but is insufficient for aggressive lymphoma with adverse prognostic factors. Dose-adjusted (DA)-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffbd463203d8e9b47fa3a895825784af
https://pubmed.ncbi.nlm.nih.gov/32880824
https://pubmed.ncbi.nlm.nih.gov/32880824
Autor:
Tsutomu, Takahashi, Fumimasa, Takahashi, Yusuke, Okada, Shunsuke, Ito, Norimi, Ugata, Yasumasa, Shimasaki, Hiroshi, Mochida, Shinichiro, Matsuda, Takahiro, Okada, Satoshi, Kumanomidou, Yumi, Jo, Koji, Adachi, Fumiyoshi, Ikejiri, Chie, Onishi, Koshi, Kawakami, Ichiro, Moriyama, Masaya, Inoue, Takaaki, Miyake, Ritsuro, Suzuki, Junji, Suzumiya
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 46(3)
Prophylactic granulocyte-colony stimulating factor(G-CSF)is necessary for some cancer patients receiving anti-cancer drugs. However, it is difficult for cancer patients in rural areas to receive G-CSF as outpatients because of inconvenient official t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3eace477440b63bd0410f02fb0cca447
https://pubmed.ncbi.nlm.nih.gov/30914584
https://pubmed.ncbi.nlm.nih.gov/30914584
Autor:
Junji Suzumiya, Ryusaku Kusunoki, Youichi Miyaoka, Akiyoshi Kanazawa, Fumimasa Takahashi, Hirofumi Fujishiro, Ichiro Moriyama, Ritsuro Suzuki, Yusuke Fujii, Yasumasa Shimasaki, Norimi Ugata, Koshi Kawakami, Michina Morioka, Shinichiro Matsuda, Satoshi Yamanouchi, Yoshitsugu Tajima, Noriyuki Hirahara, Atsuo Tokuka, Fumiyoshi Ikejiri, Kousuke Tsukano, Ayana Nagamine
Publikováno v:
Annals of Oncology. 30:vi120
Backgrounds In ATTRACTION-2 trial, nivolumab (NIVO) showed better outcome compared with best supportive care in advanced gastric cancer (AGC) patients (pts) at least two previous regimens. (NIVO has changed the treatment of AGC in Japan.) Methods: Fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73d6d8675036627e089a870c248ee89c
https://doi.org/10.1093/annonc/mdz343.009
https://doi.org/10.1093/annonc/mdz343.009
Autor:
Ichiro Moriyama, Tsutomu Takahashi, Tatsuo Kodama, Yusuke Okada, Yasunari Kawabata, Ayumi Fujimoto, Masaya Inoue, Takahiro Okada, Fumiyoshi Ikejiri, Yumi Jo, Takaaki Miyake, Fumimasa Takahashi, Shunsuke Ito, Hiroki Sonoyama, Ritsuro Suzuki, Junji Suzumiya, Shinichiro Matsuda, Norimi Ugata, Yasumasa Shimasaki, Yoshitsugu Tajima
Publikováno v:
Journal of Clinical Oncology. 37:411-411
411 Background: FOLFIRINOX (FFX) is a standard therapy for unresectable/recurrent pancreatic cancer, but it is associated with a high frequency of severe adverse events, especially blood toxicity. Human pegylated granulocyte colony-stimulating factor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::292426d751e50a6f62842da0ba51b4fb
https://doi.org/10.1200/jco.2019.37.4_suppl.411
https://doi.org/10.1200/jco.2019.37.4_suppl.411
Autor:
Masaya Inoue, Junji Suzumiya, Koji Nagafuji, Hiroaki Miyoshi, Ritsuro Suzuki, Ritsuko Seki, Shinichiro Matsuda, Koichi Ohshima
Publikováno v:
Blood. 128:108-108
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the largest subtype of lymphoma, but consists of heterogeneous groups with different prognosis. Many studies conducted to determine prognosis factors of DLBCL. Recently, several studies have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3bc27d7734d5a21fba63baa96a5fe89
https://doi.org/10.1182/blood.v128.22.108.108
https://doi.org/10.1182/blood.v128.22.108.108